MedCity News January 24, 2020
Although they’ve seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.
Agreements between drugmakers and payers under which reimbursement is contingent on specific outcomes have been a hot topic in healthcare for several years, but have been hamstrung by a variety of challenges. These include technological, infrastructural and regulatory limitations.
Yet, despite those challenges, outcome-based contracts are here to stay likely because of the potential for payers to save money. And experts anticipate that they will see continued growth.
To be sure, some of that growth is already happening. A January 2019 survey by Decision Resources Group showed that 22% of managed care...
Today's Sponsors
Today's Sponsor